期刊文献+

不同期慢性肾脏病患者骨密度及骨代谢生化指标关系 被引量:8

Association of bone mineral density and bone metabolic biomarkers in the different stages of chronic kidney disease
下载PDF
导出
摘要 目的观察不同阶段慢性肾脏病(CKD)患者的骨密度(BMD)及骨代谢情况。方法选取100例慢性肾脏病患者,根据MDRD公式计算估计肾小球滤过率(eGFR),按eGFR不同分为3组:B组(eGFR为30~59ml/min)、C组(eGFR为15~29ml/min)、D组(eGFR<15ml/min),并设同年龄非CKD患者作为对照组(A组),应用DEXA骨密度仪测定L2~L4正位及股骨颈正位BMD,4组间进行血肌酐(SCr)、全段甲状旁腺激素(iPTH)、超敏C反应蛋白(hs-CRP)、碱性磷酸酶(ALP)及BMD比较。结果不同组之间BMD及骨代谢指标有明显差异,CKD患者早期BMD已有所下降,股骨比腰椎骨质丢失更明显。BMD与iPTH呈负相关,iPTH与SCr、血磷(P)、ALP、hs-CRP呈正相关,与eGFR呈负相关,而与血钙(Ca)不相关。结论随着CKD病程的进展,BMD不断下降,肾性骨病发病增加,应引起足够重视,并于CKD早期积极干预。 Objective To investigate the bone mineral density(BMD) and bone metabolic biomarkers in the different stages of chronic kidney disease (CKD). Methods One hundred patients with CKD were enrolled in this study and divided into three groups based on the estimated glomerular filtration rate(eGFR) calculated from MDRD: Group B with eGFR 30-59 ml/min, Group C with eGFR 15-29 ml/min and Group D with eGFR 〈 15 ml/min. The age-matched non-CKD people were enrolled as control group (Group A). The level of BMD was measured at the anteroposterior sites of L2-L4 and femoral neck of the patients by using DEXA. Serum creatinin(SCr) , high sensitive C-reactive protein(hs-CRP) and bone metabolic biomarkers such as intact parathyroid hormone(iPTH) and alkaline phosphatase(ALP) were measured and compared with BMD. Results BMD and bone metabolic biomarkers showed significant differences among the four groups. BMD was decreased at CKD stage 3, and the loss of BMD was more obviously found at fenur than lumbar. BMD was negatively correlated with PTH. PTH was positively ton'elated with SCr, P, ALP, hs-CRP and negatively correlated with eGFR. There was no significant association between PTH and serum calcium level. Conclusions BMD is continuously decreased and the frequency of renal osteodystrophy is increased during the development of CKD. More attentions should be paid for the active intervention at the early stage of CKD.
出处 《实用老年医学》 CAS 2011年第4期317-320,共4页 Practical Geriatrics
关键词 慢性肾脏病 骨密度 全段甲状旁腺素 超敏C反应蛋白 chronic kidney disease bone mineral density intact parathyroid hormone high sensitive C- reactive protein
  • 相关文献

参考文献12

  • 1Beda M, Finch J, Borwn A J, et al. 1,25-dihydroxyvitamin D3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats [ J ]. Kidney Int, 1996,50( 1 ) :34-39.
  • 2Strand V, Kavanaugh AF. The role of interleukin-1 in bone resorption in rheumatoid arthritis [ J ]. Rheumatology ( Oxford) ,2004,43(Suppl 3) :11110-11116.
  • 3Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphorus p roduct with mortality risk in chronic hemodialysis patients: a national study[J]. Am J Kidney Dis, 1998, 31(4) : 607-617.
  • 4Amann K, Gross ML, London GM, et al. Hyperphosphatemia-a silent killer of patients with renal failure? [ J]. Nephrol Dial Transplant, 1999, 14(9) : 2085-2087.
  • 5Francesco L, Jorge BCA, Tilman BD, et al. Management of disturbance of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia [ J]. Nephrol Dial Transplant, 2002, 17 (5) : 723-731.
  • 6Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adult's with end-stage renal disease who are undergoing dialysis [ J ]. N Engl J Med, 2000,342 (20) : 1478-1483.
  • 7Goodman WG. Recent developments in the management of secondary hyperparathyroidism [ J ]. Kidney Int, 2001, 59 (3) : 1187-1201.
  • 8Amin N. The impact of improved phosphorus control: Use of sevelamer hydrochloride in patients with chronic renal failure [J]. Nephrol Dial Transplant, 2002, 17(2) : 340-345.
  • 9Gatoay C, Ruedin P, Slosman D, et al. Bone mineral density in patients with end-stage renal failure [ J ]. Am J Nephrol, 1993,13(2) :115-123.
  • 10Bianchi ML, Colantonio G, Montesano A,et al. Bone mass status in different degrees of chronic renal failure[ J]. Bone, 1992,13 (3) :225-228.

同被引文献53

  • 1叶青.硅溶胶对水泥基材料微观结构和力学性能的影响[J].硅酸盐学报,2008,36(4):425-430. 被引量:30
  • 2慢性肾脏病骨代谢及其疾病的临床实践指南——指南3:血清磷水平的评价[J].中国血液净化,2006,5(2):98-98. 被引量:2
  • 3Moe S, Driieke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy : a position statement from Kid- ney Disease: Improving Global Outcomes (KDIGO) [ J ]. Kidney Int, 2006,69( 11 ) :1945 - 1953.
  • 4刘永芹,薛成爱,张岐清.尿毒症患者血液透析前后心肌酶学变化及临床意义[J].中外健康文摘,2013(38):104-105.
  • 5Kidney Disease Improving Global Outcomes(KDIGO)CKD-MBD Work Group. KDIGO clinical prevention,and treatment of chonic kidney disease-mineral and bone disorder(CKD-MBD)[J].Kidney International,2009,(Supplement):S1-130.
  • 6Wu-Wong JR. Potential for vitamin D receptor agonists in the treatment of cardiovascular disease[J].British Journal of Pharmacology,2009.395-412.
  • 7Disthabanchong S, Jongjirasiri S, Adirekkiat S. Low hip bone mineral density predicts mortality in mainte- nance hemodialysis patients: a five- year follow up study[J].Blood Purl, 2014,37(1):33-38.
  • 8中华医学会骨质疏松和骨矿盐疾病分会骨质疏松及骨矿盐疾病诊疗指南(讨论稿)[J].国际内分泌代谢杂志,2006,26(24):附4.3-10.
  • 9Peretz A, Penaloza A, Mesquita M. Quantitative ultra- sound and dual X- ray absorptiometry measurements of the calcaneus in patients on maintenance hemodialysis [J].Bone, 2000,27(2):287-292.
  • 10Amemiya N, Otsubo S, Iwasa Y. Association between high- molecular-weight adiponectin and bone mineral density in hemodialysis patients[J].Clin Exp Nephrol, 2013 Jun, 17(3):411-415.

引证文献8

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部